SOX11通过调控CXCR4和FAK促进套细胞淋巴瘤的肿瘤保护性微环境相互作用
研究探讨SOX11在套细胞淋巴瘤(MCL)中促进肿瘤微环境相互作用的机制。SOX11直接结合CXCR4和PTK2(编码FAK)调控区域并上调其表达,激活PI3K/AKT和ERK1/2通路。SOX11+ MCL细胞迁移、粘附和增殖增强,对常规药物耐药增加;FAK和PI3K抑制剂可逆转这些效应。
要点
- SOX11直接上调CXCR4和FAK表达,激活PI3K/AKT和ERK1/2通路
- SOX11+ MCL细胞迁移、粘附、增殖及耐药性均高于SOX11-细胞
- FAK和CXCR4抑制剂可削弱SOX11增强的骨髓植入
核心结论
- SOX11通过直接调控CXCR4和FAK表达及FAK/PI3K/AKT通路激活,促进MCL归巢、侵袭并增加细胞粘附介导的耐药(CAM-DR), contributing to a more aggressive phenotype。
- 抑制该通路可能是克服侵袭性MCL中基质介导化疗耐药的策略。
研究设计与样本
- 研究采用SOX11+与SOX11-的异种移植模型和人原发MCL肿瘤样本进行对比。
- 体外使用MCL细胞系进行迁移、跨内皮迁移、粘附及增殖实验。
- 体内使用静脉注射MCL异种移植模型,比较SOX11+与SOX11敲低细胞的迁移、侵袭和生长。
主要发现
- SOX11+异种移植和人原发MCL肿瘤较SOX11-对应组过表达细胞迁移和基质刺激基因签名。
- SOX11+ MCL细胞较SOX11- MCL细胞具有更高的细胞迁移、跨内皮迁移、对基质细胞粘附、细胞增殖及对常规药物耐药性。
- 特异性FAK抑制阻断下游PI3K/AKT和ERK1/2介导的磷酸化。
- 特异性FAK和PI3K抑制剂将SOX11增强的MCL细胞迁移和基质相互作用降低,并将CAM-DR逆转至与SOX11- MCL细胞相同水平。
- 在静脉MCL异种移植模型中,SOX11+ MCL细胞较SOX11敲低细胞显示更高的迁移、侵袭和生长;特异性FAK和CXCR4抑制剂削弱SOX11增强的骨髓植入。
临床怎么用
- 作者认为抑制该通路可能是克服侵袭性MCL中基质介导化疗耐药的有效策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SOX11 overexpression in mantle cell lymphoma (MCL) has been associated with more aggressive behavior and worse outcome. However, SOX11 oncogenic pathways driving MCL tumor progression are poorly understood. Here, we demonstrate that SOX11 binds to regulatory regions of 2 important genes for microenvironment signals in cancer: (C-X-C motif) chemokine receptor 4 (CXCR4) and PTK2 (encoding for focal adhesion kinase [FAK]). Moreover, SOX11+ xenograft and human primary MCL tumors overexpress cell migration and stromal stimulation gene signatures compared with their SOX11- counterparts. We show that SOX11 directly upregulates CXCR4 and FAK expression, activating PI3K/AKT and ERK1/2 FAK-downstream pathways in MCL. Concordantly, SOX11+ MCL cells have higher cell migration, transmigration through endothelial cells, adhesion to stromal cells, and cell proliferation and display an increased resistance to conventional drug therapies compared with SOX11- MCL cells. Specific FAK inhibition blocks downstream PI3K/AKT- and ERK1/2-mediated phosphorylation. Additionally, specific FAK and PI3K inhibitors reduce SOX11-enhanced MCL cell migration and stromal interactions and revert cell adhesion-mediated drug resistance (CAM-DR) to the same levels as SOX11- MCL cells. In intravenous MCL xenograft models, SOX11+ MCL cells display higher cell migration, invasion, and growth compared with SOX11-knockdown cells, and specific FAK and CXCR4 inhibitors impair SOX11-enhanced MCL engraftment in bone marrow. Overall, our results suggest that SOX11 promotes MCL homing and invasion and increases CAM-DR through the direct regulation of CXCR4 and FAK expression and FAK/PI3K/AKT pathway activation, contributing to a more aggressive phenotype. Inhibition of this pathway may represent an efficient strategy to overcome stromal-mediated chemotherapy refractoriness in aggressive MCL.
引用
- Balsas P, Palomero J, Eguileor Á, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017. PMID: 28533307. doi:10.1182/blood-2017-04-776740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。